h3k27m peptide vaccine
Newly Diagnosed H3-mutated Glioma
German Cancer Research CentervaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Newly Diagnosed H3-mutated Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Valproic Acid University of Göttingen | Phase 3 | B |
Cetuximab University of Miami | Phase 1/2 | CCC |
CBL-0137 FREE BASE Children's Oncology Group | Phase 1/2 | CC |
VIPIVOTIDE TETRAXETAN Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
Imiquimod German Cancer Research Center | Phase 1 | CC |
Atezolizumab German Cancer Research Center | Phase 1 | CC |
Lorlatinib Nationwide Children's Hospital | Early Phase 1 | C |
azd1390 Children's Oncology Group | Phase 1 | NR |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →